ADAR1 Capital Management LLC Sells 270,262 Shares of Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA)

ADAR1 Capital Management LLC lowered its stake in shares of Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA - Free Report) by 61.9% in the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 166,406 shares of the company's stock after selling 270,262 shares during the period. ADAR1 Capital Management LLC owned 0.23% of Kiniksa Pharmaceuticals worth $3,292,000 at the end of the most recent quarter.

A number of other hedge funds also recently modified their holdings of KNSA. The Manufacturers Life Insurance Company purchased a new stake in Kiniksa Pharmaceuticals in the third quarter worth $354,000. FMR LLC increased its holdings in Kiniksa Pharmaceuticals by 36,925.0% in the 3rd quarter. FMR LLC now owns 696,810 shares of the company's stock worth $17,413,000 after acquiring an additional 694,928 shares during the last quarter. MetLife Investment Management LLC raised its stake in Kiniksa Pharmaceuticals by 129.1% in the 3rd quarter. MetLife Investment Management LLC now owns 21,721 shares of the company's stock valued at $543,000 after acquiring an additional 12,239 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank purchased a new stake in Kiniksa Pharmaceuticals during the third quarter valued at about $189,000. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC purchased a new position in shares of Kiniksa Pharmaceuticals in the third quarter worth about $1,105,000. Institutional investors own 53.95% of the company's stock.

Insider Activity

In other news, CAO Michael R. Megna sold 9,051 shares of the company's stock in a transaction dated Wednesday, March 12th. The stock was sold at an average price of $22.45, for a total value of $203,194.95. Following the completion of the transaction, the chief accounting officer now directly owns 26,528 shares in the company, valued at approximately $595,553.60. This represents a 25.44 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, COO Eben Tessari sold 14,000 shares of the firm's stock in a transaction dated Monday, February 10th. The shares were sold at an average price of $19.57, for a total value of $273,980.00. Following the transaction, the chief operating officer now directly owns 81,975 shares in the company, valued at approximately $1,604,250.75. This represents a 14.59 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders sold 93,766 shares of company stock worth $2,011,735. 54.57% of the stock is currently owned by insiders.

Kiniksa Pharmaceuticals Stock Performance

NASDAQ KNSA traded up $0.66 on Friday, hitting $19.31. The stock had a trading volume of 692,369 shares, compared to its average volume of 458,499. The firm has a 50-day moving average of $20.97 and a 200-day moving average of $21.62. Kiniksa Pharmaceuticals, Ltd. has a 52-week low of $16.56 and a 52-week high of $28.15. The company has a market capitalization of $1.40 billion, a price-to-earnings ratio of -137.92 and a beta of 0.31.

Kiniksa Pharmaceuticals (NASDAQ:KNSA - Get Free Report) last issued its quarterly earnings data on Tuesday, February 25th. The company reported ($0.12) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.06) by ($0.06). Kiniksa Pharmaceuticals had a negative return on equity of 7.31% and a negative net margin of 2.36%. The business had revenue of $122.50 million during the quarter, compared to analysts' expectations of $123.42 million. During the same quarter last year, the business posted $0.35 EPS. The company's quarterly revenue was up 46.9% on a year-over-year basis. As a group, research analysts anticipate that Kiniksa Pharmaceuticals, Ltd. will post -0.55 earnings per share for the current fiscal year.

Analysts Set New Price Targets

KNSA has been the topic of a number of recent research reports. Wedbush restated an "outperform" rating and set a $34.00 price target on shares of Kiniksa Pharmaceuticals in a research note on Tuesday, February 25th. Citigroup assumed coverage on Kiniksa Pharmaceuticals in a research report on Thursday, March 13th. They set a "buy" rating and a $40.00 target price on the stock. Six research analysts have rated the stock with a buy rating, According to MarketBeat, the stock has a consensus rating of "Buy" and an average price target of $37.17.

Kiniksa Pharmaceuticals Profile

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response.